| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| AMGN - Amgen Inc | BUY | 2,390 @ USD 341.11 | USD 815,253 | The ETF bought 2390 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 341.11 compared to the previous average buy price of 292.311. This is 16.7% higher than average price of previous purchases of AMGN. |
| GILD - Guild Esports Plc | BUY | 6,090 @ USD 127.12 | USD 774,161 | The ETF bought 6090 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 127.12 compared to the previous average buy price of 113.313. This is 12.2% higher than average price of previous purchases of GILD. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 1,760 @ USD 429.82 | USD 756,483 | The ETF bought 1760 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 429.82 compared to the previous average buy price of 438.397. This is -2.0% lower than average price of previous purchases of VRTX. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 860 @ USD 787.32 | USD 677,095 | The ETF bought 860 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 787.32 compared to the previous average buy price of 631.835. This is 24.6% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 1,080 @ USD 429.8 | USD 464,184 | The ETF bought 1080 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 429.8 compared to the previous average buy price of 365.299. This is 17.7% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 4,305 @ USD 93.24 | USD 401,398 | The ETF bought 4305 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 93.24 compared to the previous average buy price of 75.4685. This is 23.5% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 1,755 @ USD 209.02 | USD 366,830 | The ETF bought 1755 new shares of INSM (Insmed Inc). The shares were bought for an average price of 209.02 compared to the previous average buy price of 121.201. This is 72.5% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 255 @ USD 917.93 | USD 234,072 | The ETF bought 255 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 917.93 compared to the previous average buy price of 657.167. This is 39.7% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 1,220 @ USD 181.96 | USD 221,991 | The ETF bought 1220 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 181.96 compared to the previous average buy price of 140.179. This is 29.8% higher than average price of previous purchases of BIIB. |
| UTHR - United Therapeutics Corporation | BUY | 375 @ USD 485.77 | USD 182,164 | The ETF bought 375 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 485.77 compared to the previous average buy price of 351.954. This is 38.0% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 1,625 @ USD 105.55 | USD 171,519 | The ETF bought 1625 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 105.55 compared to the previous average buy price of 75.6477. This is 39.5% higher than average price of previous purchases of INCY. |
| ILMN - Illumina Inc | BUY | 1,275 @ USD 129.64 | USD 165,291 | The ETF bought 1275 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 129.64 compared to the previous average buy price of 98.2864. This is 31.9% higher than average price of previous purchases of ILMN. |
| MEDP - Medpace Holdings Inc | BUY | 235 @ USD 611.81 | USD 143,775 | The ETF bought 235 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 611.81 compared to the previous average buy price of 404.826. This is 51.1% higher than average price of previous purchases of MEDP. |
| RPRX - Royalty Pharma Plc | BUY | 3,585 @ USD 39.54 | USD 141,751 | The ETF bought 3585 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 39.54 compared to the previous average buy price of 35.7638. This is 10.6% higher than average price of previous purchases of RPRX. |
| RVMD - Revolution Medicines Inc | BUY | 1,560 @ USD 76.32 | USD 119,059 | The ETF bought 1560 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 76.32 compared to the previous average buy price of 43.0313. This is 77.4% higher than average price of previous purchases of RVMD. |
| NBIX - Neurocrine Biosciences Inc | BUY | 825 @ USD 143.53 | USD 118,412 | The ETF bought 825 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 143.53 compared to the previous average buy price of 130.237. This is 10.2% higher than average price of previous purchases of NBIX. |
| ROIV - Roivant Sciences Ltd | BUY | 5,665 @ USD 20.86 | USD 118,172 | The ETF bought 5665 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 20.86 compared to the previous average buy price of 13.4027. This is 55.6% higher than average price of previous purchases of ROIV. |
| GH - Guardant Health Inc | BUY | 1,040 @ USD 108.81 | USD 113,162 | The ETF bought 1040 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 108.81 compared to the previous average buy price of 57.7448. This is 88.4% higher than average price of previous purchases of GH. |
| BBIO - BridgeBio Pharma Inc | BUY | 1,595 @ USD 70.63 | USD 112,655 | The ETF bought 1595 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 70.63 compared to the previous average buy price of 45.8643. This is 54.0% higher than average price of previous purchases of BBIO. |
| SNY - Sanofi ADR | BUY | 2,235 @ USD 50.28 | USD 112,376 | The ETF bought 2235 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 50.28 compared to the previous average buy price of 50.0769. This is 0.4% higher than average price of previous purchases of SNY. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 185 @ USD 592.04 | USD 109,527 | The ETF bought 185 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 592.04 compared to the previous average buy price of 360.709. This is 64.1% higher than average price of previous purchases of MDGL. |
| SMMT - Summit Therapeutics PLC | BUY | 6,185 @ USD 17.64 | USD 109,103 | The ETF bought 6185 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.64 compared to the previous average buy price of 21.0353. This is -16.1% lower than average price of previous purchases of SMMT. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 1,330 @ USD 80.93 | USD 107,637 | The ETF bought 1330 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 80.93 compared to the previous average buy price of 49.7778. This is 62.6% higher than average price of previous purchases of IONS. |
| ASND - Ascendis Pharma AS | BUY | 505 @ USD 206.65 | USD 104,358 | The ETF bought 505 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 206.65 compared to the previous average buy price of 180.152. This is 14.7% higher than average price of previous purchases of ASND. |
| VTRS - Viatris Inc | BUY | 9,725 @ USD 10.56 | USD 102,696 | The ETF bought 9725 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 10.56 compared to the previous average buy price of 9.65723. This is 9.3% higher than average price of previous purchases of VTRS. |
| EXEL - Exelixis Inc | BUY | 2,235 @ USD 43.13 | USD 96,396 | The ETF bought 2235 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 43.13 compared to the previous average buy price of 41.0669. This is 5.0% higher than average price of previous purchases of EXEL. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 505 @ USD 180.05 | USD 90,925 | The ETF bought 505 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 180.05 compared to the previous average buy price of 125.276. This is 43.7% higher than average price of previous purchases of JAZZ. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 1,590 @ USD 56.29 | USD 89,501 | The ETF bought 1590 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 56.29 compared to the previous average buy price of 57.9808. This is -2.9% lower than average price of previous purchases of BMRN. |
| BNTX - BioNTech SE | BUY | 835 @ USD 99.71 | USD 83,258 | The ETF bought 835 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 99.71 compared to the previous average buy price of 104.896. This is -4.9% lower than average price of previous purchases of BNTX. |
| MRNA - Moderna Inc | BUY | 3,230 @ USD 24.75 | USD 79,943 | The ETF bought 3230 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 24.75 compared to the previous average buy price of 28.822. This is -14.1% lower than average price of previous purchases of MRNA. |
| RNA - Avidity Biosciences Inc | BUY | 1,065 @ USD 71.55 | USD 76,201 | The ETF bought 1065 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 71.55 compared to the previous average buy price of 38.9423. This is 83.7% higher than average price of previous purchases of RNA. |
| HALO - Halozyme Therapeutics Inc | BUY | 970 @ USD 72.82 | USD 70,635 | The ETF bought 970 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 72.82 compared to the previous average buy price of 60.4394. This is 20.5% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 990 @ USD 67.55 | USD 66,875 | The ETF bought 990 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 67.55 compared to the previous average buy price of 44.2768. This is 52.6% higher than average price of previous purchases of CYTK. |
| AXSM - Axsome Therapeutics Inc | BUY | 415 @ USD 150.36 | USD 62,399 | The ETF bought 415 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 150.36 compared to the previous average buy price of 116.833. This is 28.7% higher than average price of previous purchases of AXSM. |
| NUVL - Nuvalent Inc | BUY | 555 @ USD 109.86 | USD 60,972 | The ETF bought 555 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 109.86 compared to the previous average buy price of 83.4226. This is 31.7% higher than average price of previous purchases of NUVL. |
| MRUS - Merus BV | BUY | 630 @ USD 96.02 | USD 60,493 | The ETF bought 630 new shares of MRUS (Merus BV). The shares were bought for an average price of 96.02 compared to the previous average buy price of 65.5609. This is 46.5% higher than average price of previous purchases of MRUS. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 555 @ USD 108.75 | USD 60,356 | The ETF bought 555 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 108.75 compared to the previous average buy price of 77.0522. This is 41.1% higher than average price of previous purchases of RYTM. |
| PTCT - PTC Therapeutics Inc | BUY | 660 @ USD 82.93 | USD 54,734 | The ETF bought 660 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 82.93 compared to the previous average buy price of 56.1488. This is 47.7% higher than average price of previous purchases of PTCT. |
| PCVX - Vaxcyte Inc | BUY | 1,080 @ USD 50.24 | USD 54,259 | The ETF bought 1080 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 50.24 compared to the previous average buy price of 45.011. This is 11.6% higher than average price of previous purchases of PCVX. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 1,150 @ USD 46.79 | USD 53,809 | The ETF bought 1150 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 46.79 compared to the previous average buy price of 22.282. This is 110.0% higher than average price of previous purchases of ARWR. |
| KRYS - Krystal Biotech Inc | BUY | 240 @ USD 216.97 | USD 52,073 | The ETF bought 240 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 216.97 compared to the previous average buy price of 163.54. This is 32.7% higher than average price of previous purchases of KRYS. |
| PTGX - Protagonist Therapeutics Inc | BUY | 520 @ USD 89.86 | USD 46,727 | The ETF bought 520 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 89.86 compared to the previous average buy price of 58.2039. This is 54.4% higher than average price of previous purchases of PTGX. |
| COGT - Cogent Biosciences Inc | BUY | 1,150 @ USD 39.72 | USD 45,678 | The ETF bought 1150 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 39.72 compared to the previous average buy price of 11.8072. This is 236.4% higher than average price of previous purchases of COGT. |
| CRSP - Crispr Therapeutics AG | BUY | 755 @ USD 53.57 | USD 40,445 | The ETF bought 755 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 53.57 compared to the previous average buy price of 52.4195. This is 2.2% higher than average price of previous purchases of CRSP. |
| ALKS - Alkermes Plc | BUY | 1,375 @ USD 28.99 | USD 39,861 | The ETF bought 1375 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 28.99 compared to the previous average buy price of 30.3537. This is -4.5% lower than average price of previous purchases of ALKS. |
| KYMR - Kymera Therapeutics Inc | BUY | 595 @ USD 66.04 | USD 39,294 | The ETF bought 595 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 66.04 compared to the previous average buy price of 47.2761. This is 39.7% higher than average price of previous purchases of KYMR. |
| ADMA - ADMA Biologics Inc | BUY | 2,000 @ USD 19.21 | USD 38,420 | The ETF bought 2000 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 19.21 compared to the previous average buy price of 17.2706. This is 11.2% higher than average price of previous purchases of ADMA. |
| AKRO - Akero Therapeutics Inc | BUY | 665 @ USD 54.36 | USD 36,149 | The ETF bought 665 new shares of AKRO (Akero Therapeutics Inc). The shares were bought for an average price of 54.36 compared to the previous average buy price of 49.5569. This is 9.7% higher than average price of previous purchases of AKRO. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 785 @ USD 44.71 | USD 35,097 | The ETF bought 785 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 44.71 compared to the previous average buy price of 35.5097. This is 25.9% higher than average price of previous purchases of CRNX. |
| IMVT - Immunovant Inc | BUY | 1,465 @ USD 23.95 | USD 35,087 | The ETF bought 1465 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 23.95 compared to the previous average buy price of 18.3094. This is 30.8% higher than average price of previous purchases of IMVT. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 1,415 @ USD 24.39 | USD 34,512 | The ETF bought 1415 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 24.39 compared to the previous average buy price of 21.0124. This is 16.1% higher than average price of previous purchases of ACAD. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 165 @ USD 203.52 | USD 33,581 | The ETF bought 165 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 203.52 compared to the previous average buy price of 137.376. This is 48.1% higher than average price of previous purchases of LGND. |
| ACLX - Arcellx Inc | BUY | 460 @ USD 73 | USD 33,580 | The ETF bought 460 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 73 compared to the previous average buy price of 72.9506. This is 0.1% higher than average price of previous purchases of ACLX. |
| SRRK - Scholar Rock Holding Corp | BUY | 805 @ USD 41.47 | USD 33,383 | The ETF bought 805 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 41.47 compared to the previous average buy price of 35.1566. This is 18.0% higher than average price of previous purchases of SRRK. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 2,640 @ USD 12.44 | USD 32,842 | The ETF bought 2640 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.44 compared to the previous average buy price of 8.98129. This is 38.5% higher than average price of previous purchases of AMRX. |
| VCYT - Veracyte Inc | BUY | 660 @ USD 49.38 | USD 32,591 | The ETF bought 660 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 49.38 compared to the previous average buy price of 31.8299. This is 55.1% higher than average price of previous purchases of VCYT. |
| GRAL - GRAIL, LLC | BUY | 300 @ USD 107.69 | USD 32,307 | The ETF bought 300 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 107.69 compared to the previous average buy price of 54.5569. This is 97.4% higher than average price of previous purchases of GRAL. |
| PRAX - Praxis Precision Medicines Inc | BUY | 175 @ USD 184.25 | USD 32,244 | The ETF bought 175 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 184.25 compared to the previous average buy price of 69.1164. This is 166.6% higher than average price of previous purchases of PRAX. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 990 @ USD 30.73 | USD 30,423 | The ETF bought 990 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 30.73 compared to the previous average buy price of 16.895. This is 81.9% higher than average price of previous purchases of ARQT. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 420 @ USD 71.76 | USD 30,139 | The ETF bought 420 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 71.76 compared to the previous average buy price of 56.4627. This is 27.1% higher than average price of previous purchases of MIRM. |
| CGON - CG Oncology, Inc. Common stock | BUY | 640 @ USD 45.51 | USD 29,126 | The ETF bought 640 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 45.51 compared to the previous average buy price of 30.6284. This is 48.6% higher than average price of previous purchases of CGON. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 645 @ USD 43.94 | USD 28,341 | The ETF bought 645 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 43.94 compared to the previous average buy price of 35.946. This is 22.2% higher than average price of previous purchases of XENE. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 355 @ USD 78.88 | USD 28,002 | The ETF bought 355 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 78.88 compared to the previous average buy price of 50.7515. This is 55.4% higher than average price of previous purchases of TARS. |
| RARE - Ultragenyx | BUY | 810 @ USD 33.525 | USD 27,155 | The ETF bought 810 new shares of RARE (Ultragenyx). The shares were bought for an average price of 33.525 compared to the previous average buy price of 36.2598. This is -7.5% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 810 @ USD 33.525 | USD 27,155 | The ETF bought 810 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 33.525 compared to the previous average buy price of 36.2598. This is -7.5% lower than average price of previous purchases of RARE. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 380 @ USD 70.92 | USD 26,950 | The ETF bought 380 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 70.92 compared to the previous average buy price of 45.1151. This is 57.2% higher than average price of previous purchases of APGE. |
| IRON - Ironveld Plc | BUY | 290 @ USD 92.53 | USD 26,834 | The ETF bought 290 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 92.53 compared to the previous average buy price of 60.3601. This is 53.3% higher than average price of previous purchases of IRON. |
| TVTX - Travere Therapeutics Inc | BUY | 735 @ USD 36.01 | USD 26,467 | The ETF bought 735 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 36.01 compared to the previous average buy price of 20.7578. This is 73.5% higher than average price of previous purchases of TVTX. |
| IDYA - Ideaya Biosciences Inc | BUY | 740 @ USD 35.49 | USD 26,263 | The ETF bought 740 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 35.49 compared to the previous average buy price of 23.8847. This is 48.6% higher than average price of previous purchases of IDYA. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 1,260 @ USD 20.32 | USD 25,603 | The ETF bought 1260 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 20.32 compared to the previous average buy price of 12.0479. This is 68.7% higher than average price of previous purchases of ADPT. |
| FOLD - Amicus Therapeutics Inc | BUY | 2,550 @ USD 9.87 | USD 25,168 | The ETF bought 2550 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 9.87 compared to the previous average buy price of 7.50717. This is 31.5% higher than average price of previous purchases of FOLD. |
| DYN - Dyne Therapeutics Inc | BUY | 1,195 @ USD 20.8 | USD 24,856 | The ETF bought 1195 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 20.8 compared to the previous average buy price of 13.2928. This is 56.5% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 1,195 @ USD 20.8 | USD 24,856 | The ETF bought 1195 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 20.8 compared to the previous average buy price of 13.2928. This is 56.5% higher than average price of previous purchases of DYN. |
| DNLI - Denali Therapeutics Inc | BUY | 1,210 @ USD 19.13 | USD 23,147 | The ETF bought 1210 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 19.13 compared to the previous average buy price of 15.308. This is 25.0% higher than average price of previous purchases of DNLI. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 545 @ USD 42.2 | USD 22,999 | The ETF bought 545 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 42.2 compared to the previous average buy price of 20.8566. This is 102.3% higher than average price of previous purchases of MLYS. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 790 @ USD 28.96 | USD 22,878 | The ETF bought 790 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 28.96 compared to the previous average buy price of 17.0471. This is 69.9% higher than average price of previous purchases of CNTA. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 1,060 @ USD 21 | USD 22,260 | The ETF bought 1060 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 21 compared to the previous average buy price of 21.0087. This is 0.0% lower than average price of previous purchases of APLS. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 470 @ USD 46.08 | USD 21,658 | The ETF bought 470 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 46.08 compared to the previous average buy price of 38.0551. This is 21.1% higher than average price of previous purchases of SUPN. |
| TERN - Tern Plc | BUY | 725 @ USD 29.345 | USD 21,275 | The ETF bought 725 new shares of TERN (Tern Plc). The shares were bought for an average price of 29.345 compared to the previous average buy price of 6.48003. This is 352.9% higher than average price of previous purchases of TERN. |
| EWTX - Edgewise Therapeutics Inc | BUY | 870 @ USD 24.06 | USD 20,932 | The ETF bought 870 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 24.06 compared to the previous average buy price of 16.2581. This is 48.0% higher than average price of previous purchases of EWTX. |
| BEAM - Beam Therapeutics Inc | BUY | 835 @ USD 24.69 | USD 20,616 | The ETF bought 835 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 24.69 compared to the previous average buy price of 20.645. This is 19.6% higher than average price of previous purchases of BEAM. |
| LEGN - Legend Biotech Corp | BUY | 700 @ USD 28.19 | USD 19,733 | The ETF bought 700 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 28.19 compared to the previous average buy price of 34.2563. This is -17.7% lower than average price of previous purchases of LEGN. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 805 @ USD 22.93 | USD 18,459 | The ETF bought 805 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 22.93 compared to the previous average buy price of 11.6416. This is 97.0% higher than average price of previous purchases of AVDL. |
| TXG - 10X Genomics Inc | BUY | 955 @ USD 19.07 | USD 18,212 | The ETF bought 955 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 19.07 compared to the previous average buy price of 12.3173. This is 54.8% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 955 @ USD 19.07 | USD 18,212 | The ETF bought 955 new shares of TXG (Terex Corporation). The shares were bought for an average price of 19.07 compared to the previous average buy price of 12.3173. This is 54.8% higher than average price of previous purchases of TXG. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 1,090 @ USD 16.28 | USD 17,745 | The ETF bought 1090 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 16.28 compared to the previous average buy price of 9.58638. This is 69.8% higher than average price of previous purchases of AUPH. |
| VCEL - Vericel Corp Ord | BUY | 415 @ USD 42.54 | USD 17,654 | The ETF bought 415 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 42.54 compared to the previous average buy price of 40.708. This is 4.5% higher than average price of previous purchases of VCEL. |
| OCUL - Ocular Therapeutix Inc | BUY | 1,440 @ USD 12.13 | USD 17,467 | The ETF bought 1440 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 12.13 compared to the previous average buy price of 9.78031. This is 24.0% higher than average price of previous purchases of OCUL. |
| JANX - Janux Therapeutics Inc | BUY | 495 @ USD 34.74 | USD 17,196 | The ETF bought 495 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 34.74 compared to the previous average buy price of 27.8007. This is 25.0% higher than average price of previous purchases of JANX. |
| HRMY - Harmony Biosciences Holdings | BUY | 475 @ USD 35.34 | USD 16,787 | The ETF bought 475 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 35.34 compared to the previous average buy price of 31.8976. This is 10.8% higher than average price of previous purchases of HRMY. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 640 @ USD 26.18 | USD 16,755 | The ETF bought 640 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 26.18 compared to the previous average buy price of 14.893. This is 75.8% higher than average price of previous purchases of ZYME. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 490 @ USD 34.17 | USD 16,743 | The ETF bought 490 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 34.17 compared to the previous average buy price of 23.9518. This is 42.7% higher than average price of previous purchases of GPCR. |
| IBRX - Immunitybio Inc | BUY | 7,955 @ USD 2.08 | USD 16,546 | The ETF bought 7955 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.08 compared to the previous average buy price of 2.73018. This is -23.8% lower than average price of previous purchases of IBRX. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 3,610 @ USD 4.37 | USD 15,776 | The ETF bought 3610 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.37 compared to the previous average buy price of 5.70244. This is -23.4% lower than average price of previous purchases of RXRX. |
| SRPT - Sarepta Therapeutics Inc | BUY | 810 @ USD 19.35 | USD 15,674 | The ETF bought 810 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 19.35 compared to the previous average buy price of 33.3866. This is -42.0% lower than average price of previous purchases of SRPT. |
| VERA - Vera Therapeutics Inc | BUY | 530 @ USD 29.43 | USD 15,598 | The ETF bought 530 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 29.43 compared to the previous average buy price of 27.0681. This is 8.7% higher than average price of previous purchases of VERA. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 365 @ USD 42.71 | USD 15,589 | The ETF bought 365 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 42.71 compared to the previous average buy price of 30.5091. This is 40.0% higher than average price of previous purchases of KNSA. |
| TWST - Twist Bioscience Corp | BUY | 500 @ USD 31.11 | USD 15,555 | The ETF bought 500 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 31.11 compared to the previous average buy price of 35.7243. This is -12.9% lower than average price of previous purchases of TWST. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 180 @ USD 83.22 | USD 14,980 | The ETF bought 180 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 83.22 compared to the previous average buy price of 73.2013. This is 13.7% higher than average price of previous purchases of ANIP. |
| SYRE - Spyre Therapeutics Inc. | BUY | 500 @ USD 29.2 | USD 14,600 | The ETF bought 500 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 29.2 compared to the previous average buy price of 17.9052. This is 63.1% higher than average price of previous purchases of SYRE. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 560 @ USD 26.07 | USD 14,599 | The ETF bought 560 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 26.07 compared to the previous average buy price of 6.13701. This is 324.8% higher than average price of previous purchases of OLMA. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 715 @ USD 19.45 | USD 13,907 | The ETF bought 715 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 19.45 compared to the previous average buy price of 12.0296. This is 61.7% higher than average price of previous purchases of SNDX. |
| RLAY - Relay Therapeutics Inc | BUY | 1,723 @ USD 8.05 | USD 13,870 | The ETF bought 1723 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 8.05 compared to the previous average buy price of 4.25515. This is 89.2% higher than average price of previous purchases of RLAY. |
| STOK - Stoke Therapeutics Inc | BUY | 465 @ USD 29.82 | USD 13,866 | The ETF bought 465 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 29.82 compared to the previous average buy price of 16.6403. This is 79.2% higher than average price of previous purchases of STOK. |
| MNKD - MannKind Corp | BUY | 2,550 @ USD 5.36 | USD 13,668 | The ETF bought 2550 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.36 compared to the previous average buy price of 4.76115. This is 12.6% higher than average price of previous purchases of MNKD. |
| AGIO - Agios Pharm | BUY | 480 @ USD 28.425 | USD 13,644 | The ETF bought 480 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 28.425 compared to the previous average buy price of 36.2738. This is -21.6% lower than average price of previous purchases of AGIO. |
| IMCR - Immunocore Holdings Ltd | BUY | 340 @ USD 39.87 | USD 13,556 | The ETF bought 340 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 39.87 compared to the previous average buy price of 33.0147. This is 20.8% higher than average price of previous purchases of IMCR. |
| QURE - Uniqure NV | BUY | 460 @ USD 27.96 | USD 12,862 | The ETF bought 460 new shares of QURE (Uniqure NV). The shares were bought for an average price of 27.96 compared to the previous average buy price of 23.4798. This is 19.1% higher than average price of previous purchases of QURE. |
| HROW - Harrow Health Inc | BUY | 305 @ USD 41.02 | USD 12,511 | The ETF bought 305 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 41.02 compared to the previous average buy price of 33.7388. This is 21.6% higher than average price of previous purchases of HROW. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 1,745 @ USD 6.85 | USD 11,953 | The ETF bought 1745 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 6.85 compared to the previous average buy price of 8.23883. This is -16.9% lower than average price of previous purchases of BCRX. |
| COLL - Collegium Pharmaceutical Inc | BUY | 260 @ USD 45.6 | USD 11,856 | The ETF bought 260 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 45.6 compared to the previous average buy price of 32.4714. This is 40.4% higher than average price of previous purchases of COLL. |
| NVCR - Novocure Ltd | BUY | 930 @ USD 12.64 | USD 11,755 | The ETF bought 930 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 12.64 compared to the previous average buy price of 16.4816. This is -23.3% lower than average price of previous purchases of NVCR. |
| ARDX - Ardelyx Inc | BUY | 2,010 @ USD 5.72 | USD 11,497 | The ETF bought 2010 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 5.72 compared to the previous average buy price of 4.68859. This is 22.0% higher than average price of previous purchases of ARDX. |
| NRIX - Nurix Therapeutics Inc | BUY | 670 @ USD 17 | USD 11,390 | The ETF bought 670 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 17 compared to the previous average buy price of 12.1235. This is 40.2% higher than average price of previous purchases of NRIX. |
| INVA - Innoviva Inc | BUY | 520 @ USD 21.72 | USD 11,294 | The ETF bought 520 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 21.72 compared to the previous average buy price of 19.1104. This is 13.7% higher than average price of previous purchases of INVA. |
| DVAX - Dynavax Technologies Corporation | BUY | 975 @ USD 11.47 | USD 11,183 | The ETF bought 975 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 11.47 compared to the previous average buy price of 10.4943. This is 9.3% higher than average price of previous purchases of DVAX. |
| URGN - UroGen Pharma Ltd | BUY | 400 @ USD 27.69 | USD 11,076 | The ETF bought 400 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 27.69 compared to the previous average buy price of 15.1202. This is 83.1% higher than average price of previous purchases of URGN. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 740 @ USD 14.88 | USD 11,011 | The ETF bought 740 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 14.88 compared to the previous average buy price of 7.24762. This is 105.3% higher than average price of previous purchases of AMLX. |
| GMAB - Genmab AS | BUY | 345 @ USD 31.4 | USD 10,833 | The ETF bought 345 new shares of GMAB (Genmab AS). The shares were bought for an average price of 31.4 compared to the previous average buy price of 23.8447. This is 31.7% higher than average price of previous purchases of GMAB. |
| AMPH - Amphastar P | BUY | 385 @ USD 27.69 | USD 10,661 | The ETF bought 385 new shares of AMPH (Amphastar P). The shares were bought for an average price of 27.69 compared to the previous average buy price of 25.6242. This is 8.1% higher than average price of previous purchases of AMPH. |
| ELVN - Enliven Therapeutics Inc. | BUY | 490 @ USD 21.7 | USD 10,633 | The ETF bought 490 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 21.7 compared to the previous average buy price of 20.9223. This is 3.7% higher than average price of previous purchases of ELVN. |
| TSHA - Taysha Gene Therapies Inc | BUY | 2,280 @ USD 4.59 | USD 10,465 | The ETF bought 2280 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.59 compared to the previous average buy price of 2.9402. This is 56.1% higher than average price of previous purchases of TSHA. |
| XNCR - Xencor Inc | BUY | 595 @ USD 17.26 | USD 10,270 | The ETF bought 595 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 17.26 compared to the previous average buy price of 11.4504. This is 50.7% higher than average price of previous purchases of XNCR. |
| WVE - Wave Life Sciences Ltd | BUY | 1,360 @ USD 7.43 | USD 10,105 | The ETF bought 1360 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 7.43 compared to the previous average buy price of 8.37696. This is -11.3% lower than average price of previous purchases of WVE. |
| CVAC - CureVac NV | BUY | 1,880 @ USD 5.28 | USD 9,926 | The ETF bought 1880 new shares of CVAC (CureVac NV). The shares were bought for an average price of 5.28 compared to the previous average buy price of 4.84745. This is 8.9% higher than average price of previous purchases of CVAC. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 1,390 @ USD 7.1 | USD 9,869 | The ETF bought 1390 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.1 compared to the previous average buy price of 6.12963. This is 15.8% higher than average price of previous purchases of XERS. |
| TNGX - Tango Therapeutics Inc | BUY | 925 @ USD 10.57 | USD 9,777 | The ETF bought 925 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 10.57 compared to the previous average buy price of 6.31561. This is 67.4% higher than average price of previous purchases of TNGX. |
| FTRE - Fortrea Holdings Inc. | BUY | 755 @ USD 12.78 | USD 9,649 | The ETF bought 755 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 12.78 compared to the previous average buy price of 6.92309. This is 84.6% higher than average price of previous purchases of FTRE. |
| CSTL - Castle Biosciences Inc | BUY | 240 @ USD 39.93 | USD 9,583 | The ETF bought 240 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 39.93 compared to the previous average buy price of 22.5481. This is 77.1% higher than average price of previous purchases of CSTL. |
| ANAB - AnaptysBio Inc | BUY | 230 @ USD 41.5 | USD 9,545 | The ETF bought 230 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 41.5 compared to the previous average buy price of 24.7722. This is 67.5% higher than average price of previous purchases of ANAB. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 810 @ USD 11.62 | USD 9,412 | The ETF bought 810 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 11.62 compared to the previous average buy price of 10.5982. This is 9.6% higher than average price of previous purchases of ORIC. |
| PGEN - Precigen Inc | BUY | 2,545 @ USD 3.67 | USD 9,340 | The ETF bought 2545 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 3.67 compared to the previous average buy price of 2.43974. This is 50.4% higher than average price of previous purchases of PGEN. |
| NVAX - Novavax Inc | BUY | 1,355 @ USD 6.69 | USD 9,065 | The ETF bought 1355 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 6.69 compared to the previous average buy price of 7.3553. This is -9.0% lower than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 1,355 @ USD 6.69 | USD 9,065 | The ETF bought 1355 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 6.69 compared to the previous average buy price of 7.3553. This is -9.0% lower than average price of previous purchases of NVAX. |
| ABCL - Abcellera Biologics Inc | BUY | 2,500 @ USD 3.62 | USD 9,050 | The ETF bought 2500 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.62 compared to the previous average buy price of 3.89357. This is -7.0% lower than average price of previous purchases of ABCL. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 605 @ USD 14.93 | USD 9,033 | The ETF bought 605 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.93 compared to the previous average buy price of 9.34571. This is 59.8% higher than average price of previous purchases of PHAT. |
| GRFS - Grifols SA ADR | BUY | 1,020 @ USD 8.67 | USD 8,843 | The ETF bought 1020 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 8.67 compared to the previous average buy price of 9.32567. This is -7.0% lower than average price of previous purchases of GRFS. |
| KURA - Kura Oncology Inc | BUY | 755 @ USD 11.6 | USD 8,758 | The ETF bought 755 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 11.6 compared to the previous average buy price of 7.48497. This is 55.0% higher than average price of previous purchases of KURA. |
| PCRX - Pacira BioSciences, Inc. | BUY | 375 @ USD 23.17 | USD 8,689 | The ETF bought 375 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 23.17 compared to the previous average buy price of 23.8629. This is -2.9% lower than average price of previous purchases of PCRX. |
| EYPT - Eyepoint Pharmaceuticals Inc | BUY | 575 @ USD 14.74 | USD 8,476 | The ETF bought 575 new shares of EYPT (Eyepoint Pharmaceuticals Inc). The shares were bought for an average price of 14.74 compared to the previous average buy price of 8.97384. This is 64.3% higher than average price of previous purchases of EYPT. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 850 @ USD 9.43 | USD 8,016 | The ETF bought 850 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 9.43 compared to the previous average buy price of 7.50672. This is 25.6% higher than average price of previous purchases of DAWN. |
| ZLAB - Zai Lab Ltd | BUY | 400 @ USD 19.9 | USD 7,960 | The ETF bought 400 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 19.9 compared to the previous average buy price of 33.354. This is -40.3% lower than average price of previous purchases of ZLAB. |
| TBPH - Theravance Biopharma Inc | BUY | 420 @ USD 18.94 | USD 7,955 | The ETF bought 420 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 18.94 compared to the previous average buy price of 12.1358. This is 56.1% higher than average price of previous purchases of TBPH. |
| ERAS - Erasca Inc | BUY | 2,545 @ USD 3.07 | USD 7,813 | The ETF bought 2545 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 3.07 compared to the previous average buy price of 1.72656. This is 77.8% higher than average price of previous purchases of ERAS. |
| NTLA - Intellia Therapeutics Inc | BUY | 910 @ USD 8.55 | USD 7,781 | The ETF bought 910 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 8.55 compared to the previous average buy price of 12.1947. This is -29.9% lower than average price of previous purchases of NTLA. |
| MNMD - Mind Medicine Inc | BUY | 650 @ USD 11.88 | USD 7,722 | The ETF bought 650 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 11.88 compared to the previous average buy price of 8.7445. This is 35.9% higher than average price of previous purchases of MNMD. |
| SANA - Sana Biotechnology Inc | BUY | 2,200 @ USD 3.51 | USD 7,722 | The ETF bought 2200 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 3.51 compared to the previous average buy price of 3.18612. This is 10.2% higher than average price of previous purchases of SANA. |
| SPRY - Silverback Therapeutics Inc | BUY | 820 @ USD 9.28 | USD 7,610 | The ETF bought 820 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 9.28 compared to the previous average buy price of 13.2563. This is -30.0% lower than average price of previous purchases of SPRY. |
| VIR - Vir Biotechnology Inc | BUY | 1,155 @ USD 6.44 | USD 7,438 | The ETF bought 1155 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 6.44 compared to the previous average buy price of 5.82433. This is 10.6% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 1,155 @ USD 6.44 | USD 7,438 | The ETF bought 1155 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 6.44 compared to the previous average buy price of 5.82433. This is 10.6% higher than average price of previous purchases of VIR. |
| SVRA - Savara Inc | BUY | 1,440 @ USD 5.15 | USD 7,416 | The ETF bought 1440 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.15 compared to the previous average buy price of 2.92105. This is 76.3% higher than average price of previous purchases of SVRA. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 2,975 @ USD 2.48 | USD 7,378 | The ETF bought 2975 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.48 compared to the previous average buy price of 2.43604. This is 1.8% higher than average price of previous purchases of IOVA. |
| PAHC - Phibro Animal Health Corporation | BUY | 165 @ USD 44.33 | USD 7,314 | The ETF bought 165 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 44.33 compared to the previous average buy price of 29.2552. This is 51.5% higher than average price of previous purchases of PAHC. |
| ARVN - Arvinas Inc | BUY | 600 @ USD 12.12 | USD 7,272 | The ETF bought 600 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.12 compared to the previous average buy price of 8.94491. This is 35.5% higher than average price of previous purchases of ARVN. |
| CGEM - Cullinan Oncology LLC | BUY | 613 @ USD 11.79 | USD 7,227 | The ETF bought 613 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 11.79 compared to the previous average buy price of 7.90946. This is 49.1% higher than average price of previous purchases of CGEM. |
| ABUS - Arbutus Biopharma Corp | BUY | 1,640 @ USD 4.32 | USD 7,085 | The ETF bought 1640 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.32 compared to the previous average buy price of 3.69707. This is 16.8% higher than average price of previous purchases of ABUS. |
| PACB - Pacific Biosciences of California | BUY | 2,665 @ USD 2.63 | USD 7,009 | The ETF bought 2665 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.63 compared to the previous average buy price of 1.55777. This is 68.8% higher than average price of previous purchases of PACB. |
| REPL - Replimune Group Inc | BUY | 670 @ USD 9.53 | USD 6,385 | The ETF bought 670 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 9.53 compared to the previous average buy price of 8.93043. This is 6.7% higher than average price of previous purchases of REPL. |
| GERN - Geron Corporation | BUY | 5,325 @ USD 1.16 | USD 6,177 | The ETF bought 5325 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.16 compared to the previous average buy price of 1.49923. This is -22.6% lower than average price of previous purchases of GERN. |
| RGNX - Regenxbio Inc | BUY | 440 @ USD 13.45 | USD 5,918 | The ETF bought 440 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 13.45 compared to the previous average buy price of 9.29368. This is 44.7% higher than average price of previous purchases of RGNX. |
| KROS - Keros Therapeutics Inc | BUY | 335 @ USD 17.32 | USD 5,802 | The ETF bought 335 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 17.32 compared to the previous average buy price of 13.9394. This is 24.3% higher than average price of previous purchases of KROS. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 415 @ USD 13.28 | USD 5,511 | The ETF bought 415 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 13.28 compared to the previous average buy price of 12.3731. This is 7.3% higher than average price of previous purchases of KALV. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 1,475 @ USD 3.72 | USD 5,487 | The ETF bought 1475 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.72 compared to the previous average buy price of 3.94134. This is -5.6% lower than average price of previous purchases of PRME. |
| MGTX - MeiraGTx Holdings PLC | BUY | 680 @ USD 7.58 | USD 5,154 | The ETF bought 680 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.58 compared to the previous average buy price of 7.21731. This is 5.0% higher than average price of previous purchases of MGTX. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 1,325 @ USD 3.76 | USD 4,982 | The ETF bought 1325 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.76 compared to the previous average buy price of 2.75494. This is 36.5% higher than average price of previous purchases of MRVI. |
| PRTA - Prothena Corporation plc | BUY | 465 @ USD 10.5 | USD 4,883 | The ETF bought 465 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.5 compared to the previous average buy price of 9.14048. This is 14.9% higher than average price of previous purchases of PRTA. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 425 @ USD 10.68 | USD 4,539 | The ETF bought 425 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 10.68 compared to the previous average buy price of 6.6822. This is 59.8% higher than average price of previous purchases of FDMT. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 3,210 @ USD 1.41 | USD 4,526 | The ETF bought 3210 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.41 compared to the previous average buy price of 1.08149. This is 30.4% higher than average price of previous purchases of LXRX. |
| EOLS - Evolus Inc | BUY | 595 @ USD 6.97999 | USD 4,153 | The ETF bought 595 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 6.97999 compared to the previous average buy price of 9.07208. This is -23.1% lower than average price of previous purchases of EOLS. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 1,300 @ USD 3.13 | USD 4,069 | The ETF bought 1300 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 3.13 compared to the previous average buy price of 1.32831. This is 135.6% higher than average price of previous purchases of IRWD. |
| GLPG - Galapagos NV ADR | BUY | 125 @ USD 31.12 | USD 3,890 | The ETF bought 125 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 31.12 compared to the previous average buy price of 29.1441. This is 6.8% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 125 @ USD 31.12 | USD 3,890 | The ETF bought 125 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 31.12 compared to the previous average buy price of 29.1441. This is 6.8% higher than average price of previous purchases of GLPG. |
| HCM - HUTCHMED China Ltd | BUY | 270 @ USD 14.26 | USD 3,850 | The ETF bought 270 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 14.26 compared to the previous average buy price of 15.3796. This is -7.3% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 270 @ USD 14.26 | USD 3,850 | The ETF bought 270 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 14.26 compared to the previous average buy price of 15.3796. This is -7.3% lower than average price of previous purchases of HCM. |
| ALT - Altitude Group Plc | BUY | 725 @ USD 5.14 | USD 3,726 | The ETF bought 725 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 5.14 compared to the previous average buy price of 5.22321. This is -1.6% lower than average price of previous purchases of ALT. |
| LYEL - Lyell Immunopharma Inc | BUY | 160 @ USD 22.53 | USD 3,605 | The ETF bought 160 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 22.53 compared to the previous average buy price of 4.54122. This is 396.1% higher than average price of previous purchases of LYEL. |
| SIGA - SIGA Technologies Inc | BUY | 600 @ USD 5.95 | USD 3,570 | The ETF bought 600 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 5.95 compared to the previous average buy price of 6.76403. This is -12.0% lower than average price of previous purchases of SIGA. |
| TRDA - Entrada Therapeutics Inc | BUY | 350 @ USD 10.12 | USD 3,542 | The ETF bought 350 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 10.12 compared to the previous average buy price of 7.73239. This is 30.9% higher than average price of previous purchases of TRDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 920 @ USD 3.1 | USD 2,852 | The ETF bought 920 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.1 compared to the previous average buy price of 5.05494. This is -38.7% lower than average price of previous purchases of RCKT. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 405 @ USD 6.86999 | USD 2,782 | The ETF bought 405 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.86999 compared to the previous average buy price of 8.4482. This is -18.7% lower than average price of previous purchases of BCYC. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 555 @ USD 5 | USD 2,775 | The ETF bought 555 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 5 compared to the previous average buy price of 4.85571. This is 3.0% higher than average price of previous purchases of VNDA. |
| AUTL - Autolus Therapeutics Ltd | BUY | 1,880 @ USD 1.39 | USD 2,613 | The ETF bought 1880 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.39 compared to the previous average buy price of 1.80206. This is -22.9% lower than average price of previous purchases of AUTL. |
| ALLO - Allogene Therapeutics Inc | BUY | 1,900 @ USD 1.36 | USD 2,584 | The ETF bought 1900 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.36 compared to the previous average buy price of 1.33306. This is 2.0% higher than average price of previous purchases of ALLO. |
| AVXL - Anavex Life Sciences Corp | BUY | 745 @ USD 3.46 | USD 2,578 | The ETF bought 745 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 3.46 compared to the previous average buy price of 9.13192. This is -62.1% lower than average price of previous purchases of AVXL. |
| ACIU - AC Immune Ltd | BUY | 865 @ USD 2.9 | USD 2,509 | The ETF bought 865 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 2.9 compared to the previous average buy price of 2.46247. This is 17.8% higher than average price of previous purchases of ACIU. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 720 @ USD 3.03 | USD 2,182 | The ETF bought 720 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.03 compared to the previous average buy price of 3.30458. This is -8.3% lower than average price of previous purchases of AVIR. |
| OABI - OmniAb Inc. | BUY | 1,070 @ USD 1.86 | USD 1,990 | The ETF bought 1070 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.86 compared to the previous average buy price of 1.88729. This is -1.4% lower than average price of previous purchases of OABI. |
| EDIT - Editas Medicine Inc | BUY | 825 @ USD 2.39 | USD 1,972 | The ETF bought 825 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.39 compared to the previous average buy price of 2.73196. This is -12.5% lower than average price of previous purchases of EDIT. |
| HUMA - Humacyte Inc | BUY | 1,405 @ USD 1.32 | USD 1,855 | The ETF bought 1405 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.32 compared to the previous average buy price of 2.15781. This is -38.8% lower than average price of previous purchases of HUMA. |
| VYGR - Voyager Therapeutics Inc | BUY | 445 @ USD 3.97001 | USD 1,767 | The ETF bought 445 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 3.97001 compared to the previous average buy price of 3.88897. This is 2.1% higher than average price of previous purchases of VYGR. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 245 @ USD 6.79999 | USD 1,666 | The ETF bought 245 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 6.79999 compared to the previous average buy price of 14.2021. This is -52.1% lower than average price of previous purchases of ARCT. |
| MXCT - MaxCyte Inc | BUY | 925 @ USD 1.7 | USD 1,573 | The ETF bought 925 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.7 compared to the previous average buy price of 2.14394. This is -20.7% lower than average price of previous purchases of MXCT. |
| ALEC - Alector Inc | BUY | 915 @ USD 1.28 | USD 1,171 | The ETF bought 915 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.28 compared to the previous average buy price of 1.88934. This is -32.3% lower than average price of previous purchases of ALEC. |
| MRSN - Mersana Therapeutics Inc | BUY | 40 @ USD 27.405 | USD 1,096 | The ETF bought 40 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 27.405 compared to the previous average buy price of 0.68185. This is 3,919.2% higher than average price of previous purchases of MRSN. |
| FATE - Fate Therapeutics Inc | BUY | 945 @ USD 1.06001 | USD 1,002 | The ETF bought 945 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.06001 compared to the previous average buy price of 1.17806. This is -10.0% lower than average price of previous purchases of FATE. |
| PLRX - Pliant Therapeutics Inc | BUY | 500 @ USD 1.56999 | USD 785 | The ETF bought 500 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.56999 compared to the previous average buy price of 1.50726. This is 4.2% higher than average price of previous purchases of PLRX. |
| MGNX - MacroGenics Inc | BUY | 535 @ USD 1.45 | USD 776 | The ETF bought 535 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.45 compared to the previous average buy price of 1.57348. This is -7.8% lower than average price of previous purchases of MGNX. |
| BMEA - Biomea Fusion Inc | BUY | 595 @ USD 1.02999 | USD 613 | The ETF bought 595 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.02999 compared to the previous average buy price of 1.73305. This is -40.6% lower than average price of previous purchases of BMEA. |
| STRO - Sutro Biopharma | BUY | 680 @ USD 0.859997 | USD 585 | The ETF bought 680 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 0.859997 compared to the previous average buy price of 0.901477. This is -4.6% lower than average price of previous purchases of STRO. |
| OKUR - OKUR | BUY | 105 @ USD 2.82995 | USD 297 | The ETF bought 105 new shares of OKUR (OKUR). The shares were bought for an average price of 2.82995 compared to the previous average buy price of 6.0519. This is -53.2% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |